Leukemia Clinical Trials

Showing 3681-3700 of 5,235 trials

PKC412 and 5-Azacytidine

NCT01202877

The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.

Leukemia

M.D. Anderson Cancer Center54 participantsStarted Mar 2011

Houston, Texas, United States

COMPLETEDPhase 1

Phase I, Dose Escalation Study of Decitabine

NCT02264873

Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML). This study is based on the hypothesis that Decitabine delivered after allo-hematopoietic stem cell transplant (HSCT) in patients with leukemia will enhance disease control by the allogeneic immune system and lead to a longer disease free survival. The study is designed to provide safety data of low-dosing in the post-transplant setting.

Leukemia, Lymphoblastic, AcuteLeukemia, Myeloid AcuteHematopoetic Myelodysplasia

University of Florida3 participantsStarted Oct 2014

Gainesville, Florida, United States

COMPLETEDPhase 2

A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02875340

The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.

Carcinoma, Non-Small-Cell LungAdenocarcinoma

ValiSeek Limited8 participantsStarted Oct 2016

COMPLETEDPhase 1/2

DC Vaccination for Postremission Therapy in AML

NCT01734304

The aim of this study is to determine the feasibility and safety of an autologous DC immunotherapy in patients with AML of non-favorable risk profile.

Acute Myeloid Leukemia

Ludwig-Maximilians - University of Munich13 participantsStarted Nov 2013

Munich, Germany

PKC412 and 5-Azacytidine

Phase I, Dose Escalation Study of Decitabine

A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

DC Vaccination for Postremission Therapy in AML

Related Searches

Nilotinib Plus Pegylated Interferon-α2b in CML

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Palliative Outcome Evaluation Muenster I

Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity

Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Does Tracheal Suction During Extubation in Intensive Care Unit Decrease Functional Residual Capacity

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

Admission of Adult-onset Still Disease Patients in the ICU

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

ABLE (Arts-Based Exercise Enhancing LongEvity)

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients